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Abstract
Background: There are conflicting reports of antiretroviral therapy (ART) effectiveness comparisons between primary
healthcare (PHC) facilities and hospitals in low-income settings. This comparison has not been evaluated on a broad scale in
South Africa.
Methodology/Principal Findings: A retrospective cohort study was conducted including ART-naı ¨ve adults from 59 facilities
in four provinces in South Africa, enrolled between 2004 and 2007. Kaplan-Meier estimates, competing-risks Cox regression,
generalised estimating equation population-averaged models and logistic regression were used to compare death, loss to
follow-up (LTFU) and virological suppression (VS) between PHC, district and regional hospitals. 29 203 adults from 47 PHC
facilities, nine district hospitals and three regional hospitals were included. Patients at PHC facilities had more advanced
WHO stage disease when starting ART. Retention in care was 80.1% (95% CI: 79.3%–80.8%), 71.5% (95% CI: 69.1%–73.8%)
and 68.7% (95% CI: 67.0%–69.7%) at PHC, district and regional hospitals respectively, after 24 months of treatment
(P,0.0001). In adjusted regression analyses, LTFU was independently increased at regional hospitals (aHR 2.19; 95% CI:
1.9422.47) and mortality was independently elevated at district hospitals (aHR 1.60; 95% CI: 1.3021.99) compared to PHC
facilities after 12 months of ART. District and regional hospital patients had independently reduced probabilities of VS, aOR
0.76 (95% CI: 0.5920.97) and 0.64 (95% CI: 0.5620.75) respectively compared to PHC facilities over 24 months of treatment.
Conclusions/Significance: ART outcomes were superior at PHC facilities, despite PHC patients having more advanced
clinical stage disease when starting ART, suggesting that ART can be adequately provided at this level and supporting the
South African government’s call for rapid up-scaling of ART at the primary level of care. Further prospective research is
required to determine the degree to which outcome differences are attributable to either facility level characteristics or
patient co-morbidity at hospital level.
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Introduction
In 2007 UNAIDS estimated that there were 4.9–6.6 million
adults and children living with HIV/AIDS and that 270 000–420
000 people died annually from the disease in South Africa [1].
Although the South African Department of Health (DOH) has the
largest antiretroviral treatment (ART) programme internationally
[2], the 568 000 patients on treatment in mid-2008 represented
only 40.2% of treatment-eligible adults at that time [3]. The South
African National Strategic Plan for HIV/AIDS, published in
2007, targeted expanding ART coverage to ‘80% of those who
need it by 2011’ [4]. The government’s HIV/AIDS budgetary
allocation for the corresponding period was however well below
that required to reach this target [5,6], and at the current rate of
ART scale up an estimated 2.16 million people will die from the
disease between 2007–2011 in South Africa [7].
The government implemented rollout of ART, initiated in
2004, has endorsed the World Health Organization’s (WHO)
simplified approach with the provision of standardised first and
second line regimens provided along standardised clinical practice
guidelines. The effectiveness of ART in reducing HIV/AIDS
related morbidity and mortality globally and the need for rapid
scale-up of ART services in South Africa is well described, and
outcome data from individual sites and provinces compares well
with results from other sub-Saharan countries and the developed
world [8–11].
There is however a paucity of reliable government statistics and
publications describing clinical outcomes of ART patients
managed at routine primary healthcare (PHC) facilities outside
the Western Cape province and there are no publications directly
comparing adult programmatic outcomes between levels of care
on a broad scale in South Africa. There have been conflicting
reports of the effectiveness of ART delivery at PHC facilities when
compared to hospital-based care in sub-Saharan Africa: Outcomes
at PHC facilities were superior within a single sub district in
Lusikisiki, South Africa [12]; but a recent Malawian study
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PHC facilities [13].
The aim of this study was to compare baseline characteristics
and treatment outcomes between patients managed at different
levels in the health system in a large routine patient cohort from
four provinces in South Africa, representing over 7% of adults
enrolled in public sector ART facilities between 2004 and 2007 in
the country [14]. Additional objectives were to compare baseline
characteristics and ART outcomes between patients in different
provinces and to quantify baseline determinants of poor outcome
after starting ART.
Methods
Ethics Statement
The study was approved by the University of Cape Town
Health Sciences research ethics committee. Patient informed
consent was not required as the data collected was routine
operational monitoring data.
Study design, setting and participants
A retrospective cohort study of adults enrolling for ART
between 01 December 2004 and 31 December 2007 at 59 public
health facilities in both urban and rural areas, including 47 PHC
facilities, nine district hospitals and three regional hospitals was
conducted. All sites were part of the government-run ART
program and were supported by the nongovernmental organisa-
tion (NGO) Absolute Return for Kids (currently named
Kheth’Impilo). Facility visits were free of charge for HIV positive
patients. All sites supported by the NGO that had an electronic
patient monitoring system were included in the study.
Twenty-eight sites were in the Western Cape province, nine in
the Eastern Cape, 15 in KwaZulu-Natal and seven in Mpuma-
langa. There were two, three, three, and one district hospitals
included in the above provinces respectively with an additional
three regional hospitals in KwaZulu-Natal. The majority of
patients lived in peri-urban informal settlements, but the Eastern
Cape, KwaZulu-Natal and Mpumalanga also included patients
from rural areas. Unemployment rates (2007) in the Western
Cape, Eastern Cape, KwaZulu-Natal and Mpumalanga were
15.7%, 26.1%, 30.0% and 22.0% respectively, and crude death
rates for these provinces were 9.8, 13.0, 11.5 and 11.8 deaths per
1000 population (2001) respectively [15]. The vast majority of
patients accessing care at all levels of the healthcare system are
impoverished, with lack of adequate sanitation and malnutrition
being common. Sites started recruiting patients at various time-
points between December 2004 and December 2007.
Adults with a CD4 cell count ,200 cells/mL and/or a WHO
stage IV defining illness were eligible to start treatment as per the
South African national treatment guidelines. All ART-naı ¨ve adults
($16 years) with documented date of birth, gender, date of starting
ART and who initiated triple combination ART were eligible to
be included in analyses.
Standardised first-line regimens consisted of two nucleoside
reverse transcriptase inhibitors and one non-nucleoside reverse
transcriptase inhibitor. Workup and maintenance of patients on
ART was implemented according to the National Department of
Health guidelines, which are standardized across facilities and
between health system levels. Prior to starting ART, patients
underwent clinical and immunological staging, and received HIV
education and treatment adherence counselling. Patients on
treatment had to attend monthly for clinical checks and to collect
their treatment from pharmacies. CD4 cell count was measured at
ART initiation and at six monthly intervals, and viral load was
monitored six-monthly on treatment. Laboratory monitoring was
performed by the South African National Health Laboratory
Services, which were off-site except in the case of larger hospitals.
Patients were followed-up until 31 March 2008 or until the
NGO exited from a site (18 sites in the Western Cape, one in
KwaZulu-Natal and one site in the Eastern Cape were exited
between March 2005 and February 2008). Outcome measures
were death, loss to follow-up (LTFU) and virological suppression
(VS). Deaths were reported by the clinic staff or the patient’s
community-based adherence counsellor. LTFU was defined as no
visit to the clinic for three months or more beyond the last missed
appointment date and the patient was not known to have died or
moved to another treatment program or place. Patients who were
late for appointments or LTFU were attempted to be traced at
home by adherence counsellors. A conservative measurement of
time was used, being from the date of ART initiation until the date
of last follow-up visit. In time-to-event statistical analyses, follow-
up times of patients who transferred to other facilities were
censored at the date of last visit.
Data collection and statistical analyses
Individual-level patient data was collected prospectively for
routine monitoring purposes by designated site-based data
capturers using Microsoft Access databases, which was pooled
on a quarterly basis to a central data warehouse using standard
operating procedures. Continual data cleaning and quality control
routines were implemented to enhance data validity.
Groups were compared using the Kruskal-Wallis and Pearson’s
x2 tests for continuous and categorical data respectively.
Virological suppression was calculated as the proportion of
patients with a viral load ,400 copies/ml with binomial exact
confidence intervals. Kaplan-Meier estimates of mortality and
retention in care (RIC) were calculated. An intention-to-treat
analysis was performed ignoring treatment stoppages or interrup-
tions. The logrank test was used to compare groups. The temporal
distribution of deaths and LTFU were assessed by plotting
smoothed instantaneous hazard curves from product-limit analy-
ses, using weighted kernel density estimates based on an
Epanechnikov function.
Multivariable competing-risks Cox proportional hazards regres-
sion models were used to examine baseline factors associated with
time to death and LTFU after 12 months of ART, including only
patients with available baseline CD4 cell count and WHO clinical
staging. Competing-risks regression accounts for the fact that the
risks of death and LTFU may not be independent, and allows the
baseline hazard to differ between the competing risks [16].
Regression models were adjusted for all available baseline
characteristics, controlled for heterogeneity due to different site
cohorts, stratified by event type, and robust variance adjustment
was used due to the twin strata for death and LTFU. Proportional
hazards assumptions were confirmed not to be violated using
scaled Schoenfeld residuals and log-log plots of survival against
analysis time for each of the covariates.
Multivariable generalised estimating equation population-aver-
aged models were used to analyse the effect of patient and
available site-level factors associated with VS up to 24 months of
ART, adjusting for available baseline variables and time on ART.
An exchangeable working correlation structure was selected and
the results verified to be similar assuming other applicable
correlation structures. A sensitivity analysis using multivariable
logistic regression of baseline factors associated with VS at 12
months was performed, to assess if results were consistent. All
analyses were performed with Stata version 9.2 (College Station,
Texas, USA).
Better PHC Site ART Outcomes
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Baseline characteristics
A total of 42 237 patient database records were screened for
eligibility for the study and 29 203 patients were included in the
analysis. Patients were excluded from the analysis for the following
reasons: 3581 had missing demographic data, 3733 were ART-
experienced, 2147 were aged ,16 years when starting ART and
3573 started ART after 31 December 2007.
The median age was 34.3 years (IQR: 29.4–40.7) and 68.1%
were women (table 1). The median baseline CD4 cell count was
114 cells/mL (IQR: 57–166) and increased marginally from 111
cells/mL (IQR 54–170) in 2004 to 118 cells/mL (IQR 61–170) in
2007. Overall, 75.8% of patients had a baseline WHO clinical
stage of III or IV.
The number of patients enrolled at PHC facilities, district
hospitals and regional hospitals were 19 273 (66%), 2483 (8.5%)
and 7447 (25.5%) respectively. The mean number of patients
enrolled per facility at regional hospitals was 2482 compared to
410 at PHC sites. Baseline CD4 cell counts were similar between
facility levels, however patients enrolling at PHC sites had more
severe clinical stage disease (P,0.001), table 1.
The number of patients enrolled in the Western Cape, Eastern
Cape, KwaZulu-Natal and Mpumalanga provinces were 11557
(39.6%), 1583 (5.4%), 15 540 (53.2%) and 523 (1.8%) respectively
with corresponding median baseline CD4 cell counts of 112 cells/
mL (IQR: 54–165), 128 cells/mL (IQR: 69–180), 113 cells/mL
(IQR: 57–164) and 125 cells/mL (IQR: 59–199). The Western and
Eastern Cape had the highest proportions with advanced clinical
disease, with 79.0%, 79.0%, 73.8% and 74.4% of patients having
a baseline WHO stage of III or IV in the Western Cape, Eastern
Cape, KwaZulu-Natal and Mpumalanga respectively (P,0.001).
Over 29 297 person-years of observation 1656 (5.7%) patients
died after starting ART, 3401 (11.7%) were LTFU and 1606
(5.5%) transferred-out to other facilities. Following 24 months of
treatment, the overall cumulative probability of reported mortality
was 7.4% (95% CI: 7.1%–7.8%) and patient RIC was 76.1%
(95% CI: 75.5%–76.8%), figure 1. The proportion of patients
LTFU after 24 months was 12.0% (95% CI: 11.1%–12.8%). The
hazard of death decreased dramatically after the first six months of
treatment (figure 2), with mortality rates being 11.1 (95% CI:
10.5–11.7) and 2.1 (95% CI: 2.0–2.2) deaths/100 person-years
during months 0–6 and 6–24 of treatment respectively. The
hazard of LTFU was also highest initially, but decreased
progressively as the duration of treatment increased.
The proportion of eligible patients having available viral load
results in the database varied from 56.2% at 12 months to 62.8% at
36 months. Overall virological suppression was good; being greater
than 85% at all six-monthly measurement intervals up to 36 months
of treatment (figure 1).Compared to patients aged $20 years, VS in
young adults aged 16–19 years was reduced, being 74.6% (95% CI:
62.5%–84.5%); P=0.001) and 68.1% (95% CI: 52.8 –80.9%;
P,0.001) at 6 and 12 months respectively. There were more
women amongst this age group (89.1% versus 68.0% in ages $20
years; P,0.001) however there were no other differences in baseline
clinical or demographic variables between these age categories.
Comparison of ART outcomes between treatment facility
levels and patient factors associated with poor outcomes
During the study period, 1076 (5.6%), 182 (7.3%) and 398 (5.3%)
patients died (P=0.001), and 1719 (8.9%), 348 (14.0%) and 1334
(17.9%) become LTFU (P,0.001) at PHC facilities, district and
regional hospitals respectively. Figure 3 compares Kaplan-Meier
cumulative estimates of RIC, mortality, LTFU and transfer-out
between levels of care. RIC was superior at PHC facilities, being
80.1% (95% CI: 79.3%–80.8%) compared to 71.5% (95% CI:
69.1%–73.8%) at district and 68.7% (95% CI: 67.0%–69.7%) at
regional hospitals after 24 months of ART (logrank P,0.0001).
Mortality was highest at district hospitals, being 10.3% (95% CI:
8.9%–12.0%) compared to 7.3% (95% CI: 6.9%–7.8%) at PHC
facilities and 6.8% (95% CI: 6.1%–7.5%) at regional hospitals after
24 months (logrank P,0.0001). LTFU was lowest at PHC sites and
highest at regional hospitals (logrank P,0.0001). Transfer-out
increased dramatically after 24 months at regional hospitals.
Table 1. Baseline characteristics of adults starting ART stratified by facility levels.
All Primary healthcare District Hospitals Regional Hospitals P-value
Number of patients, n (%) 29 203 (100) 19 273 (66.0) 2483 (8.5) 7447 (25.5)
Number of sites 59 47 9 3
Mean patients enrolled/site, n 495 410 311 2482
Median age, y (IQR) 34.3 (29.4–40.7) 34.0 (29.2–40.4) 34.7(29.9–41.6) 34.8 (29.7–41.5) 0.001
Male, n (%) 9 317 (31.9%) 6164 (32.0) 779 (31.4) 2374 (31.9) 0.83
WHO stage $III, n (%)
a 16 714 (75.8) 11 515 (79.3) 934 (58.3) 4265 (72.2) ,0.001
Unstaged, n (%)
b 7 163 (24.5) 4774 (24.6) 882 (35.5) 1537 (20.6) ,0.001
Baseline CD4 cell count (cells/mL),
median (IQR)
114 (I57–166) 113 (57–165) 109 (54–155) 116 (57–170) 0.001
CD4 cell count unavailable, n (%)
b 5734 (19.6) 4367 (22.7) 517 (20.8) 850 (11.4) ,0.001
Western Cape patients, n (%)
c 11 557 (39.6)
b 10 708 (92.7) 849 (7.3) 0 (0)
Eastern Cape patients, n (%)
c 1583 (5.4)
b 1255 (79.3) 328 (20.7) 0 (0)
KwaZulu-Natal patients, n (%)
c 15 540 (53.2)
b 6823 (43.9) 1270 (8.2) 7447 (47.9)
Mpumalanga patients, n (%)
c 523 (1.8)
b 487 (93.1) 36 (6.9) 0 (0)
aPercentage of available results.
bPercentage of total patients.
cPercentage of patients per province.
IQR-interquartile range; WHO-world health organization.
doi:10.1371/journal.pone.0012888.t001
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factors associated with death and LTFU after 12 months of
treatment in patients with all baseline measurements available
(n=18 866). There were no significant differences in baseline
demographic variables between the full cohort and this subgroup;
however more patients were treated at regional hospitals in the
subgroup, with 12 268 (65.0%), 1330 (7.1%) and 5268 (27.9%)
patients treated at PHC, district and regional hospitals respectively.
Compared to PHC sites, mortality was independently elevated
at district hospitals (aHR 1.60; 95% CI: 1.30–1.99). LTFU was
independently elevated at regional hospitals, aHR 2.19 (95% CI:
1.94–2.47). Patients in the Eastern Cape, KwaZulu-Natal and
Mpumalanga provinces had independently increased probabilities
of mortality compared to the Western Cape. Adjusted probabilities
of LTFU between provinces were similar. WHO stage IV disease
was associated with an increased probability of death (aHR 4.84;
95% CI: 3.72–6.31) as was decreasing CD4 cell count, with the
risk being greatest with CD4 cell counts ,25 cells/mL (aHR 3.80;
95% CI: 2.48–5.82). Older age was inversely related to the risk of
LTFU. Patients enrolling in later years had considerably elevated
risks of LTFU compared to patients enrolled in 2004, aHR 6.18
(95% CI: 4.30–8.89; 2007 cohort).
The median CD4 cell increase after twelve months of treatment
was 159 cells/mL (IQR: 81–254), with no difference between PHC
sites and hospitals (P=0.44). PHC sites had considerably greater
proportions of patients having available viral load results, with
73.0% (n=5657), 29.4% (n=293) and 25.4% (n=803) of viral
load results being available at 12 months at PHC, district and
hospital facilities respectively. Overall VS was highest at PHC
facilities, being 88.0% (95% CI: 87.6%–88.4%, n=22 320)
compared to 86.9% (95% CI: 84.8%–88.8%, n=1141) and
82.2% (95% CI: 81.0%–83.4%, n=4615) at district and regional
hospitals respectively at any time-point on treatment, P,0.001.
Overall VS was highest in the Western Cape being 89.5% (95%
CI: 88.9%–90.1%, n=10 443) compared to 83.7% (95% CI:
82.1%–85.2%, n=2187), 86.3% (95% CI: 85.7%–86.8%, n=14
264) and 78.9% (95% CI: 75.1%–82.3%, n=535) in the Eastern
Figure 1. Kaplan-Meier estimates of death, retention-in-care; and proportions virologically suppressed adults according to
duration of ART.
a Cumulative probabilities with Greenwood point-wise 95% confidence intervals.
b Proportions with binomial exact 95%
confidence intervals.
c Proportion of patients eligible for viral load tests with a recorded database result. RIC, Remaining in care; VS, Virologic
suppression (,400 copies/ml).
doi:10.1371/journal.pone.0012888.g001
Figure 2. Smoothed hazard estimates of death and loss to
follow-up according to duration of ART.
doi:10.1371/journal.pone.0012888.g002
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doi:10.1371/journal.pone.0012888.g003
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point on treatment, P,0.001.
Figure 4 compares virological suppression between facility
levels. A multivariable model predicting virological suppression at
any follow-up duration up to 24 months of ART adjusting for
baseline variables and duration of ART was derived, which
included 10 458 patients having viral load data and all baseline
values available. Of these, 7914 (75.7%), 445 (4.3%) and 2099
(20.1%) were from PHC facilities, district and regional hospitals
respectively. District and regional hospital patients were found to
have independently reduced probabilities of VS compared to PHC
facility patients, aOR 0.76 (95% CI: 0.5920.97) and 0.64 (95%
CI: 0.56–0.75) respectively (table 3). In addition, young adults
aged 16–19 years had a reduced probability of VS compared to
those aged 20–29 years (aOR 0.44; 95% CI: 0.27–0.72). Patients
aged $40 years had a higher probability of VS (aOR 1.69; 95%
CI: 1.33–2.16). Patients in the Eastern Cape, KwaZulu-Natal and
Mpumalanga provinces had independently reduced probabilities
of VS compared to the Western Cape.
In sensitivity analyses of baseline factors associated with VS at
12 months adjusting for all available baseline measurements
(n=4885), district and regional hospitals patients similarly had
reduced probabilities of VS compared to PHC facility patients,
aOR 0.73 (95% CI: 0.4921.09) and 0.58 (95% CI: 0.45–0.75)
respectively. Young adults aged 16–19 years also had indepen-
dently reduced probability of VS compared to those aged 20–29
years, aOR 0.26 (95% CI: 0.12–0.55). Patients outside the
Western Cape similarly had independently reduced probabilities
of VS; aOR 0.41 (95% CI: 0.27–0.60), aOR 0.72 (95% CI: 0.56–
0.94) and aOR 0.20 (95% CI: 0.09–0.41) for the Eastern Cape,
KwaZulu-Natal and Mpumalanga respectively compared to the
Western Cape.
Discussion
This is one of the first large-scale direct comparisons of the
effectiveness of routine adult ART provision between health
system levels at facilities across multiple provinces in South Africa.
Overall outcomes were found to be superior at PHC clinics when
compared to hospitals, despite PHC patients having more
advanced clinical stage disease when starting ART. These findings
concur with a South African study that compared outcomes
between children initiated on ART at PHC clinics and hospitals
within the Western Cape province [17].
Table 2. Multivariable competing-risks Cox proportional hazards model of factors associated with death and loss to follow-up
after 12 months of ART (n=18 866)
a.
Death Loss to follow-up
Patient Factor Adjusted Hazard Ratio 95% CI P-value Adjusted Hazard Ratio 95% CI P-value
Male gender 1.14 1.00–1.30 0.047 1.20 1.09–1.33 0.001
Age
b 1.06 0.99–1.15 0.104 0.89 0.84–0.94 ,0.001
WHO stage 1/II
c 1.00 1.00
stage III 1.85 1.47–2.32 ,0.001 1.15 1.01–1.32 0.036
stage IV 4.84 3.72–6.31 ,0.001 1.97 1.67–2.34 ,0.001
Baseline CD4 cell count (cells/mL):
.200
c 1.00 1.00
50–199 1.61 1.09–2.38 0.017 1.31 1.07–1.62 0.009
25–49 3.07 2.00–4.75 ,0.001 1.51 1.18–1.92 0.001
,25 3.80 2.48–5.82 ,0.001 1.49 1.17–1.89 0.001
Year of starting ART:
2004
c 1.00 1.00
2005 0.87 0.67–1.14 0.332 3.05 2.09–4.44 ,0.001
2006 0.69 0.53–0.90 0.006 6.78 4.59–9.72 ,0.001
2007 0.49 0.37–0.65 ,0.001 6.18 4.30–8.89 ,0.001
Province
Western Cape
c 1.00 1.00
Eastern Cape 1.77 1.28–2.44 0.001 0.90 0.67–1.19 0.454
KwaZulu-Natal 1.42 1.20–1.67 ,0.001 0.92 0.80–1.06 0.243
Mpumalanga 2.70 1.37–5.33 0.004 1.56 0.89–2.74 0.121
Facility level
Primary healthcare
c 1.00 1.00
District hospitals 1.60 1.30–1.99 ,0.001 1.36 1.11–1.66 0.002
Regional hospitals 1.07 0.91–1.27 0.376 2.19 1.94–2.47 ,0.001
aModels are adjusted for all variables shown.
b10-year age increase.
cReference category.
WHO-World Health Organisation; CI-confidence interval; ART-antiretroviral therapy.
doi:10.1371/journal.pone.0012888.t002
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data from research sentinel sites in South Africa as well as with
developed world cohorts [9–11] and the results support the
previously observed trend toward increased LTFU amongst
patients enrolled in more recent years in low-income settings
[8,18]. The most important reason for this trend is likely to be the
increase in patient numbers at individual sites over time, with
some clinics managing over 3000 ART patients; however it may
also reflect that patients LTFU in earlier years had a greater
probability of re-entering treatment than patients LTFU nearer
the end of the study period. The steady increase in LTFU is
concerning in the context of massive scale-up over the next 5–10
years and the paucity of published data detailing outcomes
amongst patients in developing countries after five years of
treatment.
Although facility-level quality of care variables were not directly
measured in this study, the proportions of patients with available
on-treatment viral load measurements was higher at PHC sites,
and this may be used as a proxy indicator for site-based quality of
care [8]. Facility-level factors that may negatively impact patient
outcomes at hospital-based outpatient services include higher
patient loads and high patient/staff ratios, which lead to reduced
individual patient attention from nurses and counsellors and a
resultant decreased quality of care, increased LTFU and treatment
failure. Environmental factors that may affect outcomes between
levels of care include the distance, difficulty and cost of transport
to health facilities [19,20]. Access to care at the primary level is
likely to be easier and cheaper for patients, with services being
more aligned to ongoing patients’ needs and a probable decreased
time to treatment initiation.
The independently higher risks of mortality and treatment
failure amongst patients in the Eastern Cape, KwaZulu-Natal and
Mpumalanga is a concern and is not explained by differences in
baseline clinical or immunological parameters between these
provinces. The reasons for this are probably multi-factorial and
include differences in socioeconomic status, access to healthcare
services as well as differences in the quality of health service
delivery including patient/staff ratios. Further research is needed
to explain and validate these results including larger sample sizes
from the Eastern Cape and Mpumalanga.
Poor virological response is an important factor associated with
disease progression and death, predisposes to the development of
drug-resistance and reduces future treatment options [21].
Although overall virologic suppression was high and compared
favourably with other studies [9,10], young adults in this data are
shown to have a greater risk of virologic failure. This trend is in
keeping with other cohorts from South Africa and Haiti [22,23],
which demonstrated an association with poor adherence, high-
lighting the need for specific interventions to improve adherence in
this age group.
The failure of the median baseline CD4 cell count in this dataset
to increase substantially over time is concerning and contrasts with
other published data from South Africa covering the same time
period [24]. This may reflect that as the ART program expanded
into new areas over time, the baseline CD4 cell counts of new
patients starting treatment in the previously unreached areas
Figure 4. Proportions of patients with virological suppression at primary healthcare facilities and hospitals.
a a Vertical bars indicate
95% binomial exact confidence intervals.
b Proportion of patients eligible for viral load tests with a recorded database result. PHC-primary healthcare
facilities.
doi:10.1371/journal.pone.0012888.g004
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number of people who urgently require ART in the country.
Given the recognition of temporal trends in baseline CD4 cell
count as a proxy measure of access and uptake of treatment, the
poor increase of this data element raises concerns of the impact of
the national ART program on broader demographic outcomes in
the country and supports the argument for urgent expansion and
scale-up of ART services [8,25].
The rapid expansion of quality ART programs within the
limited budget envelope in South Africa will require the
implementation of innovative and cost-effective approaches to
service delivery. Several obstacles to the rapid scale-up of ART
services have been identified at sites incorporated in this analysis,
including underutilisation of PHC clinics, rapid increases in
patient numbers leading to overcrowding of individual sites, as
well as an over-reliance on doctor-driven services. Rapid scale-up
necessitates broadening of services to the primary healthcare level
facilitating both initiation of new patients and down-referral of
stable patients from hospitals and large community health centres
to smaller PHC clinics as has been effective in the Lusikisiki sub-
district [12].
Nurse-monitored services have recently been shown to be
effective in an observational study in Lesotho [26] and non-
inferior to doctor-monitored care in a randomised non-inferiority
trial [27]. Nurses are however also in short supply and under
pressure [28], and expanding elements of service delivery to the
community should be explored. Several programmes in South
Africa have had success with the use of community workers to
provide adherence support to ART patients, however the full
utility of this cadre of health worker has not been maximally
developed or evaluated. Simple health systems interventions, such
as streamlining of patient flow within sites and increasing the time
between clinic appointments or pharmacy pick-up dates for stable
patients (in order to decrease the daily patient load thus improving
service quality at each site) may also be effective in facilitating
rapid scale-up of quality services and should be prioritised under
the umbrella of clinical governance.
Maintaining good monitoring systems becomes more critical
and more complex as the numbers of treatment providers, patients
on treatment and duration of treatment increases. The paper-
based system rolled out by the Western Cape DOH is the more
referenced in South Africa [8,17] due to the failure to successfully
implement an electronic ART monitoring systems across South
Africa. The national DOH is currently piloting a number of
electronic systems to identify an appropriate electronic solution for
monitoring the rollout nationally. Electronic systems have however
produced poor quality data in a number of cohorts in low-income
settings, and require sufficient resources and adequately trained
data staff to ensure adequate data quality [29].
The strengths of this study are that pooled data from a large
number of patients and sites in different settings were used, and
individual-level data was collected prospectively enabling explo-
ration and adjustment of patient factors associated with outcomes.
Data from provinces which have not yet had outcomes published
were included in analyses.
Non HIV-related co-morbidities and detailed HIV-related
diagnoses are not included in the routine monitoring data
collected from ART patients in South Africa, due to the increased
difficulty and expense that capturing this information on a large
scale would necessitate. These data elements could therefore not
be included in analyses in this study. Patients with co-morbidities
may be more likely to initiate ART at hospital level and also to
have poorer outcomes, therefore these are potential confounders
which may negatively affect overall outcome estimates at hospital
level compared to PHC sites. Differences in outcomes between
facilities may therefore be partially attributable to these confound-
ers, the magnitude of which is indeterminate in this study,
although it is unlikely to be large as a relatively lesser proportion of
patients have serious non HIV-related morbidity or HIV-related
morbidity not reflected in baseline immunological status or WHO
clinical staging. Other studies comparing outcomes between health
system levels have also not included these data elements in
analyses [12,13]. Research has yet to be conducted in low-income
countries to determine the degree to which outcome differences
between facility levels are attributable to facility characteristics or
patient clinical co-morbidity at hospital levels, and would require
prospective studies that capture data beyond what is collected on a
routine programmatic basis.
This study is a retrospective analysis using routine data with its
inherent limitations, it is likely however to be indicative of the
situation at an operational level. Viral load results were available
for approximately 60% of eligible patients which may bias VS
estimates; however availability was three-fold higher than from a
number of other sub-Saharan ART programs [30]. Over 30% of
patients LTFU from ART programs have been found to have died
in studies linking the vital status of patients LTFU with national
death registries [31,32]. Due to the large cohort size in this study
we did not link patients LTFU with death registries, and were
therefore not able to determine the proportion of unascertained
deaths amongst those LTFU or to calculate corrected mortality
figures. It is possible that misclassification of patients as LTFU
instead of transferred-out was differentially increased at regional
hospitals compared to other facilities, as regional hospitals had the
highest rates of transfer-out and the highest patient loads
Table 3. Multivariable generalized estimating equation
population-averaged model of virological suppression up to
24 months of ART (n=10 458)
a.
Variable Adjusted OR 95% CI P-value
Male gender 0.89 0.80–1.00 0.051
Age: 16–19 years 0.44 0.27–0.72 0.001
20–29 years
b 1.00
30–39 years 1.12 0.99–1.26 0.069
$40 years 1.69 1.33–2.16 ,0.001
WHO stage: I/II
b 1.00
III/IV 0.86 0.76–0.97 0.018
Baseline CD4 cell count (mL) 1.00 0.99–1.00 0.149
Western Cape province
b 1.00
Eastern Cape province 0.41 0.32–0.52 ,0.001
KwaZulu-Natal province 0.69 0.59–0.82 ,0.001
Mpumalanga province 0.30 0.17–0.51 ,0.001
Primary healthcare facilities
b 1.00
District hospitals 0.76 0.59–0.97 0.030
Regional hospitals 0.64 0.56–0.75 ,0.001
ART duration 6 months
b 1.00
ART duration 12 months 0.83 0.78–0.92 ,0.001
ART duration 18–24 months 0.83 0.73–0.95 0.007
aEstimates adjusted for all variables shown and year of starting ART.
bReference category.
WHO-World Health Organisation; CI-confidence interval; ART-antiretroviral
therapy.
doi:10.1371/journal.pone.0012888.t003
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at regional hospitals although the magnitude is unlikely to be large.
As the sites included were not a random sample of all public ART
facilities in each province, results may not necessarily be well-
generalisable to the whole of each province. The sample size in
Mpumalanga was small in relation to the samples from other
provinces, therefore outcomes from this province should be viewed
cautiously.
Household socio-economic data is not collected as part of
routine monitoring of ART patients in South Africa, and there is
little reliable data comparing socioeconomic indices between
patients accessing care at different levels of the health system in
South Africa. Socioeconomic data could therefore not be included
in analyses when comparing outcomes between health system
levels; previous studies investigating this question similarly did not
include this type of data [12,13]. There is however no reason to
suggest that patients attending hospitals have significantly worse
socioeconomic indices than patients attending PHC clinics,
therefore this limitation is not expected to be a confounder of
the results. Indeed, patients at PHC clinics are more likely to have
worse socioeconomic indices, as PHC clinics have more rural
patients than hospitals (which are mostly urban-based), and
poverty is worse in rural than in urban areas [33].
In conclusion, these results suggest that ART program
management at the primary level of the healthcare system in a
developing country setting is equally or more effective than in a
hospital-based setting. Further operational research should be
conducted on the implementation of nurse-led services and
potentially devolving aspects of ART care to the community.
There remains a need for innovative solutions to programme
expansion to increase enrolment for the growing number of
patients needing treatment, manage stable patients, reduce
programme costs, as well as to increase access to more effective
treatments and patient monitoring systems such as viral resistance
testing. The ongoing challenges faced in the struggle to scale up
high-quality ART services are formidable, but addressing these
effectively has the potential to considerably improve HIV/AIDS
related morbidity and mortality in South Africa.
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